Skip to main content
Top
Published in: International Cancer Conference Journal 4/2017

01-10-2017 | Case report

Periaortitis induced by epirubicin and cyclophosphamide for a patient with advanced breast cancer

Authors: Masayuki Inoue, Hiroshi Nakagomi, Haruka Nakada, Kazushige Furuya, Kou Ikegame, Hideki Watanabe, Atsushi Yamamoto, Atsushi Takano, Yoshiaki Miyasaka, Michiya Yasutome, Masao Hada, Masao Omata

Published in: International Cancer Conference Journal | Issue 4/2017

Login to get access

Abstract

Aortitis is an extremely rare condition, and it may mimic febrile neutropenia during cancer chemotherapy. A 55-year-old female diagnosed with T2N1M1 stage IV breast carcinoma received chemotherapy with EC (epirubicin 90 mg/m2 and cyclophosphamide 600 mg/m2 every 3 weeks). At the eleventh day after the first administration of EC, she developed a high-grade fever of 38 °C and stomatitis. We started the intravenous administration of antibiotics at hospitalization, because the laboratory data showed normal white blood cell values 3800/μl but a severe inflammatory reaction (CRP 25.13 mg/dl). The fever and high CRP value continued, and the WBC rose to 14,500/μl at 20th day. However, her condition was stable. On the 25th day after the administration of EC, she complained of back pain, so we performed computed tomography (CT) again and observed thickening of the rind surrounding the descending aorta and bilateral pleural effusion, indicating acute periaortitis. We performed examinations concerning vasculitis and connective tissue disease, but the values were all within normal ranges showing no relationship with other diseases. We stopped the administration of antibiotics on the 20th day, and while we did not administer corticosteroids, however, the fever was resolved and her WBC decreased. She was discharged on day 33, and the other chemotherapy was restarted with pertuzumab, trastuzumab and docetaxel. The patient has remained well without inflammatory reactions. CT at 90 days after EC therapy showed the resolution of the thickened rind of the descending aorta and no aneurysmic changes.
Literature
1.
go back to reference Sickles EA, Greene WH, Wiernik PH (1975) Clinical presentation of infection in granulocytopenic patients. Arch Intern Med 135:715–719CrossRefPubMed Sickles EA, Greene WH, Wiernik PH (1975) Clinical presentation of infection in granulocytopenic patients. Arch Intern Med 135:715–719CrossRefPubMed
2.
go back to reference Horowitz HW (2013) Fever of unknown origin or fever of too many origins? N Engl J Med 368:197–199CrossRefPubMed Horowitz HW (2013) Fever of unknown origin or fever of too many origins? N Engl J Med 368:197–199CrossRefPubMed
3.
go back to reference Murakami S, Saito H, Ohe M et al (2013) Periaortitis associated with anti-neutrophil cytoplasmic antibodies induced by bevacizumab combination therapy. Intern Med 52:589–591CrossRefPubMed Murakami S, Saito H, Ohe M et al (2013) Periaortitis associated with anti-neutrophil cytoplasmic antibodies induced by bevacizumab combination therapy. Intern Med 52:589–591CrossRefPubMed
4.
go back to reference Adiga GU, Elkadi D, Malik SK et al (2009) Abdominal aortitis after use of granulocyte colony-stimulating factor. Clin Drug Investig 29:821–825CrossRefPubMed Adiga GU, Elkadi D, Malik SK et al (2009) Abdominal aortitis after use of granulocyte colony-stimulating factor. Clin Drug Investig 29:821–825CrossRefPubMed
5.
go back to reference Darie C, Boutalba S, Fichter P et al (2004) Aortitis after G-CSF injections. Rev Med Interne 25:225–229CrossRefPubMed Darie C, Boutalba S, Fichter P et al (2004) Aortitis after G-CSF injections. Rev Med Interne 25:225–229CrossRefPubMed
6.
go back to reference Freifeld AG, Bow EJ, Sepkowitz KA et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 52:e56–e93CrossRefPubMed Freifeld AG, Bow EJ, Sepkowitz KA et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 52:e56–e93CrossRefPubMed
9.
go back to reference Kitahara T, Hiromura K, Maezawa A et al (1997) Case of propylthiouracil-induced vasculitis associated with anti-neutrophil cytoplasmic antibody (ANCA); review of literature. Clin Nephrol 47:336–340PubMed Kitahara T, Hiromura K, Maezawa A et al (1997) Case of propylthiouracil-induced vasculitis associated with anti-neutrophil cytoplasmic antibody (ANCA); review of literature. Clin Nephrol 47:336–340PubMed
10.
go back to reference Zeina AR, Slobodin G, Naschitz JE et al (2007) Isolated periaortitis: clinical and imaging characteristics. Vasc Health Risk Manag 3:1083–1086PubMedPubMedCentral Zeina AR, Slobodin G, Naschitz JE et al (2007) Isolated periaortitis: clinical and imaging characteristics. Vasc Health Risk Manag 3:1083–1086PubMedPubMedCentral
11.
go back to reference Mizushima I, Inoue D, Yamamoto M et al (2014) Clinical course after corticosteroid therapy in IgG4-related aortitis/periaortitis and periarteritis: a retrospective multicenter study. Arthritis Res Ther 16:R156CrossRefPubMedPubMedCentral Mizushima I, Inoue D, Yamamoto M et al (2014) Clinical course after corticosteroid therapy in IgG4-related aortitis/periaortitis and periarteritis: a retrospective multicenter study. Arthritis Res Ther 16:R156CrossRefPubMedPubMedCentral
12.
go back to reference Kiyohara H, Hisamatsu T, Matsuoka K et al (2015) Crohn’s disease in which the patient developed aortitis during treatment with Adalimumab. Intern Med 54:1725–1732CrossRefPubMed Kiyohara H, Hisamatsu T, Matsuoka K et al (2015) Crohn’s disease in which the patient developed aortitis during treatment with Adalimumab. Intern Med 54:1725–1732CrossRefPubMed
13.
go back to reference Hamasaki H, Hakoshima M, Yanai H (2015) Periaortitis induced by metformin. Diabetes Metab 41:344–345CrossRefPubMed Hamasaki H, Hakoshima M, Yanai H (2015) Periaortitis induced by metformin. Diabetes Metab 41:344–345CrossRefPubMed
14.
go back to reference Loricera J, Blanco R, Hernandez JL et al (2015) Non-infectious aortitis: a report of 32 cases from a single tertiary centre in a 4-year period and literature review. Clin Exp Rheumatol 33:S-19-31PubMed Loricera J, Blanco R, Hernandez JL et al (2015) Non-infectious aortitis: a report of 32 cases from a single tertiary centre in a 4-year period and literature review. Clin Exp Rheumatol 33:S-19-31PubMed
15.
go back to reference Rozin AP, Bar-Shalom R, Strizevsky A et al (2007) Fever due to aortitis. Clin Rheumatol 26:265–267CrossRefPubMed Rozin AP, Bar-Shalom R, Strizevsky A et al (2007) Fever due to aortitis. Clin Rheumatol 26:265–267CrossRefPubMed
Metadata
Title
Periaortitis induced by epirubicin and cyclophosphamide for a patient with advanced breast cancer
Authors
Masayuki Inoue
Hiroshi Nakagomi
Haruka Nakada
Kazushige Furuya
Kou Ikegame
Hideki Watanabe
Atsushi Yamamoto
Atsushi Takano
Yoshiaki Miyasaka
Michiya Yasutome
Masao Hada
Masao Omata
Publication date
01-10-2017
Publisher
Springer Japan
Published in
International Cancer Conference Journal / Issue 4/2017
Electronic ISSN: 2192-3183
DOI
https://doi.org/10.1007/s13691-017-0302-1

Other articles of this Issue 4/2017

International Cancer Conference Journal 4/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine